var data={"title":"Anakinra: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Anakinra: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5645?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=anakinra-patient-drug-information\" class=\"drug drug_patient\">see &quot;Anakinra: Patient drug information&quot;</a> and <a href=\"topic.htm?path=anakinra-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Anakinra: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135465\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Kineret</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135466\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Kineret</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135484\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antirheumatic, Disease Modifying;</li>\n      <li>\n        Interleukin-1 Receptor Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135468\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neonatal-onset multisystem inflammatory disease (NOMID):</b> SubQ: Initial: 1 to 2 mg/kg daily in 1 to 2 divided doses; adjust dose in 0.5 to 1 mg/kg increments as needed; usual maintenance dose: 3 to 4 mg/kg daily (maximum: 8 mg/kg daily). <b>Note:</b> Once-daily administration is preferred; however, the dose may also be divided and administered twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Familial Mediterranean fever (off-label use):</b> SubQ: 100 mg once daily (Ben-Zvi 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gout, treatment of acute flares (when conventional therapy is ineffective, contraindicated, or not tolerated) (off-label use):</b> SubQ: 100 mg once daily (Ghosh 2013; Ottaviani 2013; So 2007). Most patients received therapy for 3 days (So 2007). Additional data may be necessary to further define the role of anakinra in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pericarditis (recurrent) (off-label use):</b> SubQ: 100 mg once daily. Dosing based on limited data with treatment periods up to 6 months (Brucata 2016; Cantarini 2010). Additional data is necessary to further define the role of anakinra in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis (RA):</b> SubQ: 100 mg once daily (administer at approximately the same time each day)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16330957\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=anakinra-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Anakinra: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neonatal-onset multisystem inflammatory disease (NOMID):</b> Infants, Children, and Adolescents: SubQ: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Juvenile idiopathic arthritis, systemic (off-label use):</b> Children and Adolescents: SubQ: Initial: 1 to 2 mg/kg once daily; maximum initial dose: 100 mg; if no response after 1 to 2 weeks, may titrate up to 4 mg/kg once daily (maximum: 200 mg/day) (Dewitt 2012; Hedrich 2012; Lequerr&eacute; 2008; Nigrovi 2011; Quartier 2011; Ringold 2013).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135469\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135470\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute or end-stage renal disease (ESRD): Consider administering the prescribed dose every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable (&lt;2.5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous ambulatory peritoneal dialysis (CAPD): Not dialyzable (&lt;2.5%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13258473\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135448\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kineret: 100 mg/0.67 mL (0.67 mL) [contains disodium edta, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135434\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135450\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Allow solution to warm to room temperature prior to use (30 minutes). Inject into outer area of upper arms, abdomen (do not use within 2 inches of belly button), front of middle thighs, or upper outer buttocks. Rotate injection sites; do not administer into tender, swollen, bruised, red, or hard skin or skin with scars or stretch marks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135449\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neonatal-onset multisystem inflammatory disease:</b> Treatment of neonatal-onset multisystem inflammatory disease (NOMID).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b>  Reduction in signs and symptoms and slowing the progression of structural damage of moderately to severely active rheumatoid arthritis (RA) in patients 18 years and older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25816343\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Familial Mediterranean fever; Gout, treatment of acute flares (when conventional therapy is ineffective, contraindicated, or not tolerated); Juvenile idiopathic arthritis; Pericarditis, recurrent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135491\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anakinra may be confused with amikacin, Ampyra</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kineret may be confused with Amikin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135440\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (12% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (NOMID: 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (RA: 49%; neutralizing: 2%; no correlation of antibody development and adverse effects)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (RA: 39%; serious infection: 2% to 3%; including cellulitis, pneumonia, and bone and joint infections)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (RA: 71%; mild: 73%; moderate: 24%; severe: 2% to 3%; NOMID: 16%; mild: 76%; moderate: 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (NOMID: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (NOMID: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (NOMID: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (RA: 8%), diarrhea (RA: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Eosinophilia (RA: 9%), decreased white blood cell count (RA: 8%), change in platelet count (RA; decreased: 2%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (NOMID)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypercholesterolemia (RA)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (NOMID)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Hepatitis (noninfectious), hypersensitivity reaction (including anaphylaxis, angioedema, pruritus, skin rash, urticaria), increased serum transaminases, metastases (malignant lymphoma, malignant melanoma), opportunistic infection, thrombocytopenia (including severe)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135453\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to <i>E. coli</i>-derived proteins, anakinra, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135438\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported; discontinue use if severe hypersensitivity occurs; medications for the treatment of hypersensitivity reactions should be available for immediate use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Associated with an increased risk of serious infections in rheumatoid arthritis studies. Anakinra should not be initiated in patients with an active infection. If a patient receiving anakinra for rheumatoid arthritis develops a serious infection, therapy should be discontinued; if a patient receiving anakinra for neonatal-onset multisystem inflammatory disease (NOMID) develops a serious infection, the risk of a NOMID flare should be weighed against the risks associated with continued treatment. Safety and efficacy have not been evaluated in immunosuppressed patients or patients with chronic infections; the impact on active or chronic infections has not been determined. Immunosuppressive therapy (including anakinra) may lead to reactivation of latent tuberculosis or other atypical or opportunistic infections; test patients for latent TB prior to initiation, and treat latent TB infection prior to use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site reactions: Injection site reactions commonly occur (within first 4 weeks of therapy) and are generally mild with a duration of 14 to 28 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: May affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neutropenia: A decrease in neutrophil count may occur during treatment. Assess neutrophil count at baseline, monthly for 3 months, then every 3 months for up to 1 year. In a limited number of patients with NOMID, neutropenia resolved over time with continued anakinra administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Use with caution in patients with asthma; may have increased risk of serious infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment; extended dosing intervals (every other day) are recommended for severe renal insufficiency (CrCl &lt;30 mL/minute) and ESRD.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use caution due to the potential higher risk for infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy; live vaccines should not be given concurrently. There is no data available concerning the effects of therapy on vaccination or secondary transmission of live vaccines in patients receiving therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298752\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135442\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9246&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anakinra may enhance the adverse/toxic effect of Abatacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Interleukin-1 Receptor Antagonist may enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anakinra may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135444\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135456\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Information related to the use of anakinra during pregnancy is limited (Makol 2011; Ostensen 2011). Specific guidelines for use in pregnancy are not available (Saag [ACR] 2008); use should not be continued during pregnancy until more data is available (Makol 2011; Ostensen 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women exposed to anakinra during pregnancy may contact the Organization of Teratology Information Services (OTIS), Rheumatoid Arthritis and Pregnancy Study at 1-877-311-8972. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135457\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if anakinra is excreted in breast milk. The manufacturer recommends that caution be exercised when administering anakinra to nursing women. Endogenous interleukin-1 receptor antagonist can be found in breast milk (Buescher 1996).  Until additional information is available, use should be avoided in nursing women (Makol 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135446\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (baseline, then monthly for 3 months, then every 3 months for a period up to 1 year); TB test (baseline); serum creatinine; signs/symptoms of infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135437\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antagonist of the interleukin-1 (IL-1) receptor. Endogenous IL-1 is induced by inflammatory stimuli and mediates a variety of immunological responses, including degradation of cartilage (loss of proteoglycans) and stimulation of bone resorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135452\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ: 95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 4 to 6 hours; Severe renal impairment (CrCl &lt;30 mL/minute): ~7 hours; ESRD: 9.7 hours (Yang 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: SubQ: 3 to 7 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135455\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Kineret Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/0.67 mL (0.67 mL): $167.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135458\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kineret (AT, AU, BB, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IL, IS, IT, KR, LT, LV, MT, NL, NO, PL, PT, RO, SE, SG, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis Rheumatol</i>. 2017;69(4):854-862. doi:10.1002/art.39995.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/27860460/pubmed\" target=\"_blank\" id=\"27860460\">27860460</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. <i>JAMA</i>. 2016;316(18):1906-1912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/27825009/pubmed\" target=\"_blank\" id=\"27825009\">27825009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buescher ES, Malinowska I. Soluble receptors and cytokine antagonists in human milk. <i>Pediatr Res</i>. 1996;40(6):839-844.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/8947960 /pubmed\" target=\"_blank\" id=\"8947960 \">8947960 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cantarini L, Lucherini OM, Cimaz R, Galeazzi M. Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. <i>Clin Exp Rheumatol</i>. 2010;28(5):802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21029567/pubmed\" target=\"_blank\" id=\"21029567\">21029567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen S, Hurd E, Cush J, et al, &ldquo;Treatment of Rheumatoid Arthritis With Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, in Combination With Methotrexate: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo; <i>Arthritis Rheum</i>, 2002, 46(3):614-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/11920396/pubmed\" target=\"_blank\" id=\"11920396\">11920396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dewitt EM, Kimura Y, Beukelman T, et al; Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(7):1001-1010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/22290637/pubmed\" target=\"_blank\" id=\"22290637\">22290637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleischmann RM, Schechtman J, Bennett R, et al, &ldquo;Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist (r-metHuIL-1ra), in Patients With Rheumatoid Arthritis: A Large, International, Multicenter, Placebo-Controlled Trial,&rdquo; <i>Arthritis Rheum</i>, 2003, 48(4):927-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/12687534/pubmed\" target=\"_blank\" id=\"12687534\">12687534</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleischmann RM, Tesser J, Schiff MH, et al, &quot;Safety of Extended Treatment With Anakinra in Patients With Rheumatoid Arthritis,&quot; <i>Ann Rheum Dis</i>, 2006,65(8):1006-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/16396977/pubmed\" target=\"_blank\" id=\"16396977\">16396977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Genovese MC, Cohen S, Moreland L, et al, &ldquo;Combination Therapy With Etanercept and Anakinra in the Treatment of Patients With Rheumatoid Arthritis Who Have Been Treated Unsuccessfully With Methotrexate,&rdquo; <i>Arthritis Rheum</i>, 2004, 50(5):1412-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/15146410/pubmed\" target=\"_blank\" id=\"15146410\">15146410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23650178\"></a>Ghosh P, Cho M, Rawat G, Simkin PA, et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. <i>Arthritis Care Res</i> (<i>Hoboken</i>). 2013;65(8):1381-1384. doi: 10.1002/acr.21989.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/23650178/pubmed\" target=\"_blank\" id=\"23650178\">23650178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22083619\"></a>Hedrich CM, Bruck N, Fiebig B, Gahr M. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). <i>Rheumatol Int</i>. 2012;32(11):3525-3530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/22083619/pubmed\" target=\"_blank\" id=\"22083619\">22083619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kineret (anakinra) [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lequerr&eacute; T, Quartier P, Rosellini D, et al; Soci&eacute;t&eacute; Francophone pour la Rhumatologie et les Maladies Inflammatoires en P&eacute;diatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. <i>Ann Rheum Dis</i>. 2008;67(3):302-308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/17947302/pubmed\" target=\"_blank\" id=\"17947302\">17947302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. <i>Drugs</i>. 2011;71(15):1973-1987.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21985166 /pubmed\" target=\"_blank\" id=\"21985166 \">21985166 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21280009\"></a>Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. <i>Arthritis Rheum</i>. 2011;63(2):545-555.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21280009/pubmed\" target=\"_blank\" id=\"21280009\">21280009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ostensen M, F&ouml;rger F. Treatment with biologics of pregnant patients with rheumatic diseases. <i>Curr Opin Rheumatol</i>. 2011;23(3):293-298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21346578 /pubmed\" target=\"_blank\" id=\"21346578 \">21346578 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24432362\"></a>Ottaviani S, Molt&oacute; A, Ea HK, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. <i>Arthritis Res Ther</i>. 2013;15(5):R123.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/24432362/pubmed\" target=\"_blank\" id=\"24432362\">24432362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? <i>Arthritis Rheum</i>. 2009;60(1):264-268.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/19116906/pubmed\" target=\"_blank\" id=\"19116906\">19116906</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21173013\"></a>Quartier P, Allantaz, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). <i>Ann Rheum Di</i>s. 2011;70(5):747-754.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21173013/pubmed\" target=\"_blank\" id=\"21173013\">21173013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/27457514/pubmed\" target=\"_blank\" id=\"27457514\">27457514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rigante D, Leone A, Marrocco R, et al, &ldquo;Long-Term Response After 6-Year Treatment With Anakinra and Onset of Focal Bone Erosion in Neonatal-Onset Multisystem Inflammatory Disease (NOMID/CINCA),&rdquo; <i>Rheumatol Int</i>, 2011, 31(12):1661-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/21240490/pubmed\" target=\"_blank\" id=\"21240490\">21240490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ringold S, Weiss PF, Beukelman T, et al; American College of Rheumatology. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Rheum</i>. 2013;65(10):2499-2512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/24092554/pubmed\" target=\"_blank\" id=\"24092554\">24092554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Arthritis Rheum</i>. 2008;59(6):762-784.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/18512708 /pubmed\" target=\"_blank\" id=\"18512708 \">18512708 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sibley CH, Plass N, Snow J, et al,&rdquo; Sustained Response and Prevention of Damage Progression in Patients With Neonatal-Onset Multisystem Inflammatory Disease Treated With Anakinra: A Cohort Study to Determine Three- and Five-Year Outcomes,&rdquo; <i>Arthritis Rheum</i>, 2012, 64(7):2375-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/22294344/pubmed\" target=\"_blank\" id=\"22294344\">22294344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17352828\"></a>So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. <i>Arthritis Res Ther</i>. 2007;9(2):R28. doi: 10.1186/ar2143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/17352828/pubmed\" target=\"_blank\" id=\"17352828\">17352828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang B, Baughman S, and Sullivan JT, &ldquo;Pharmacokinetics of Anakinra in Subjects With Different Levels of Renal Function,&rdquo; <i>Clin Pharmacol Ther</i>, 2003, 74(1):85-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anakinra-drug-information/abstract-text/12844139/pubmed\" target=\"_blank\" id=\"12844139\">12844139</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9246 Version 128.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135465\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F135466\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F135484\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F135468\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F16330957\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F135469\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F135470\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13258473\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135448\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F135434\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F135450\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F135449\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25816343\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F135491\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135440\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135453\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135438\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298752\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F135442\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135444\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F135456\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F135457\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F135446\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135437\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F135452\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F135455\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F135458\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9246|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=anakinra-patient-drug-information\" class=\"drug drug_patient\">Anakinra: Patient drug information</a></li><li><a href=\"topic.htm?path=anakinra-pediatric-drug-information\" class=\"drug drug_pediatric\">Anakinra: Pediatric drug information</a></li></ul></div></div>","javascript":null}